Myriad Genetics

Myriad Genetics

Yahoo Finance • 8 days ago

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the largest individual-patient-data meta-a... Full story

Yahoo Finance • 9 days ago

1 Unpopular Stock That Should Get More Attention and 2 We Find Risky

1 Unpopular Stock That Should Get More Attention and 2 We Find Risky Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about... Full story

Yahoo Finance • 17 days ago

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

SALT LAKE CITY, June 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to p... Full story

Yahoo Finance • last month

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris wi... Full story

Yahoo Finance • 2 months ago

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

SALT LAKE CITY, May 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, joins forces with Nobody Wants This actress Jackie Tohn to raise awareness about the... Full story

Yahoo Finance • 2 months ago

Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock

We just covered 10 Stocks That Tanked: Why Larry Robbins’ Top Picks Are Struggling in 2026 and Myriad Genetics, Inc. (NASDAQ:MYGN) ranks 8th on this list. Myriad Genetics, Inc. (NASDAQ:MYGN) has been a staple in the 13F portfolio of Glenv... Full story

Yahoo Finance • 2 months ago

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

SALT LAKE CITY, April 30, 2026 (GLOBE NEWSWIRE) -- The latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, reveals that... Full story

Yahoo Finance • 3 months ago

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

Myriad Genetics, Inc. SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at the Society of... Full story

Yahoo Finance • 3 months ago

3 Healthcare Stocks with Open Questions

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and as a result, the industry has faired... Full story

Yahoo Finance • 3 months ago

Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as investors reacted to escalating uncertainty tied to the U.S.-Iran conflict and poli... Full story

Yahoo Finance • 4 months ago

Liquid Biopsy Products Market Report 2026-2031 Featuring Analysis of Roche, Illumina, Qiagen, MDxHealth, Novogen, BGI, Myriad Genetics and More

Company Logo Dublin, March 20, 2026 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Product Market Report: Trends, Forecast and Competitive Analysis to 2031" has been added to ResearchAndMarkets.com's offering. The global liquid biopsy product m... Full story

Yahoo Finance • 4 months ago

Myriad Genetics Gains FDA Nod For Ovarian Cancer Test

(RTTNews) - Myriad Genetics, Inc., (MYGN) announced that the U.S. FDA has approved its MyChoice CDx Test as the companion diagnostic for Zejula, a PARP inhibitor developed by GSK, for patients with advanced ovarian cancer. The approval is... Full story

Yahoo Finance • 4 months ago

2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns whe... Full story

Yahoo Finance • 4 months ago

Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc

Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted to the company's successful pivot into the high-growth sectors of AI infrastruct... Full story

Yahoo Finance • 4 months ago

Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 6.9% in the afternoon session after its President and CEO, Samraat Raha, purchased a significant amount of company stock. According to filings, Raha bou... Full story

Yahoo Finance • 4 months ago

Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Al... Full story

Yahoo Finance • 4 months ago

2 Unprofitable Stocks on Our Buy List and 1 We Brush Off

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising. Fi... Full story

Yahoo Finance • 4 months ago

PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key measure of inflation at t... Full story

Yahoo Finance • 4 months ago

Personalized Medicine Market Competitive Landscape Report 2025: Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

Company Logo Personalized Medicine Market Poised for Tremendous Growth by 2033The global personalized medicine market, valued at approximately US$ 585.53 billion in 2026, is projected to soar to nearly US$ 1.00 trillion by 2033. A report... Full story

Yahoo Finance • 4 months ago

Cancer Diagnostics Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

Dublin, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The "Cancer Diagnostics Market Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts" report has been added to Rese... Full story